Inotiv, Inc. Q1 2026 Earnings Recap

NOTV Q1 2026 February 9, 2026

Get alerts when NOTV reports next quarter

Inotiv's first quarter 2026 demonstrated strong year-over-year growth in its Discovery and Safety Assessment (DSA) business, with a 12% revenue increase, although overall revenue was slightly up by 0.8%, hindered by challenges in the Research Model Services (RMS) segment.

Earnings Per Share Miss

$-0.72 vs $-0.64 est.

-12.9% surprise

Revenue Miss

120879000 vs 120908300 est.

-0.0% surprise

Market Reaction

1-Day -13.63%

5-Day -31.91%

30-Day -20.63%

See NOTV alongside your other holdings

Add to your portfolio — free

Key Takeaways

DSA revenues rose to $48 million, a 12% increase year-over-year, driven by greater demand for discovery pharmacology and surgical services.
Net new DSA awards surged 27% to $53.6 million, highlighting robust booking momentum.
RMS revenue declined 5.4% due to lower sales in Non-Human Primates (NHPs), exacerbated by decreased volumes shipped.
The company is actively optimizing its operations, exiting two leased facilities to improve margins by Q3 2026.
A financial covenant waiver was secured, reflecting ongoing efforts to enhance the balance sheet and refinance debt.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NOTV on AllInvestView.

Previous Q4 2025